{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Codexis, Inc. technically bullish or bearish?
As of June 6, 2025, Codexis, Inc. shows a mildly bearish trend, indicated by daily moving averages and Bollinger Bands, despite a mildly bullish MACD, suggesting overall market weakness and a cautious outlook.
Who are in the management team of Codexis, Inc.?
As of March 2022, the management team of Codexis, Inc. includes Mr. Bernard Kelley (Independent Chairman), Mr. John Nicols (CEO), and several independent directors: Dr. Jennifer Aaker, Mr. Thomas Baruch, Ms. Pam Cheng, Mr. Byron Dorgan, and Mr. David Smith. They are responsible for the company's strategic direction and governance.
What does Codexis, Inc. do?
Codexis, Inc. is a protein engineering company that develops biocatalysts for pharmaceuticals and fine chemicals, classified as a micro-cap with a market cap of approximately $183.92 million. As of March 2025, it reported net sales of $8 million and a net loss of $21 million.
How big is Codexis, Inc.?
As of Jun 18, Codexis, Inc. has a market capitalization of 183.92 million, with net sales of 49.81 million and a net profit of -74.46 million over the latest four quarters. The company reported shareholder's funds of 66.93 million and total assets of 149.01 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
